Benefit — EMA stance
What Snapshot-grade EMA-facing AI evidence actually saves you
EMA scientific-advice rapporteurs and CHMP reviewers apply the Reflection Paper principles when AI shows up in trial conduct or MAA-supporting analysis. Dated independent evidence reshapes those conversations before they land.
The three moments where it matters
- EMA scientific-advice request. Rapporteur asks about AI validation + human oversight for the trial-eligibility surface. Independent monitoring evidence is the direct answer.
- Centralised MAA submission. CHMP reviewer asks about AI/ML-based components in the application. Explainability + monitoring records support the benefit-risk narrative.
- Post-authorisation pharmacovigilance. EMA follow-up on AI-touched subgroups relies on the monitoring baseline. Snapshot provides that baseline.
Dollar frame
EMA scientific-advice non-conforming outcome: EU market-access delay 12-24 months post-approval; opportunity cost typically $50M-$500M per program depending on indication.
MAA reviewer follow-up round: a single Day-120 List-of-Questions round with AI-specific queries typically drives $500K-$3M in Reg Affairs + biostats + medical-writing response cost.
Preventive discipline cost: $499 Snapshot. Independent AI-monitoring record aligned to EMA Reflection Paper expectations.
Who at your org cares
- VP Regulatory Affairs (EU) — scientific-advice + MAA stance
- Chief Medical Officer — benefit-risk explainability
- Head of Global Market Access — EU launch-timing risk
- Chief Quality Officer — QMS alignment across FDA + EMA
What "having it" looks like
Green: Snapshot on file. Independent monitoring baseline + validation + limitations documented. EMA question answered in the same cycle.
Red: Vendor screenshot as the only AI-monitoring record. Rapporteur pushback lengthens the advice loop. MAA timeline slips.
$499. 3 business days.
Independent-verifier record aligned to EMA Reflection Paper expectations. On your sponsor's actual AI surface.
Buy $499